Nexterone is a drug owned by Baxter Healthcare Corp. It is protected by 2 US drug patents filed in 2013. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 13, 2029. Details of Nexterone's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | Active |
| US6869939 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
May, 2022
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nexterone's patents.
Latest Legal Activities on Nexterone's Patents
Given below is the list of recent legal activities going on the following patents of Nexterone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical | 04 Dec, 2022 | US6869939 |
| Correspondence Address Change Critical | 04 Dec, 2022 | US7635773 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Jun, 2021 | US7635773 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 09 Jun, 2016 | US6869939 |
| Mail-Petition Decision - Denied | 14 Jul, 2014 | US6869939 |
| Petition Decision - Denied | 14 Jul, 2014 | US6869939 |
| Email Notification Critical | 07 Jan, 2014 | US6869939 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 Jan, 2014 | US6869939 |
| Correspondence Address Change Critical | 06 Jan, 2014 | US6869939 |
| Change in Power of Attorney (May Include Associate POA) Critical | 25 Jun, 2013 | US7635773 |
US patents provide insights into the exclusivity only within the United States, but Nexterone is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nexterone's family patents as well as insights into ongoing legal events on those patents.
Nexterone's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nexterone's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 13, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nexterone Generic API suppliers:
Amiodarone Hydrochloride is the generic name for the brand Nexterone. 25 different companies have already filed for the generic of Nexterone, with Upsher Smith Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nexterone's generic
About Nexterone
Nexterone is a drug owned by Baxter Healthcare Corp. Nexterone uses Amiodarone Hydrochloride as an active ingredient. Nexterone was launched by Baxter Hlthcare in 2008.
Approval Date:
Nexterone was approved by FDA for market use on 24 December, 2008.
Active Ingredient:
Nexterone uses Amiodarone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Amiodarone Hydrochloride ingredient
Dosage:
Nexterone is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG/100ML (1.5MG/ML) | INJECTABLE | Prescription | INJECTION |
| 50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INJECTION |
| 360MG/200ML (1.8MG/ML) | INJECTABLE | Prescription | INJECTION |